Jacob Ablin

Prof. Jacob Ablin

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2015 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
WHWinfried Häuser
Winfried Häuser
Jacob AblinJacob Ablin
Jacob Ablin
MFMary-Ann Fitzcharles
Mary-Ann Fitzcharles
GLGeoffrey Littlejohn
Geoffrey Littlejohn
Juan V. LucianoJuan V. Luciano
Juan V. Luciano
BWBrian Walitt
Brian Walitt

1 July 2008 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SOS Oren
S Oren
MMM Mandelboim
M Mandelboim
YBY Braun-Moscovici
Y Braun-Moscovici
DPD Paran
D Paran
Jacob AblinJacob Ablin
Jacob Ablin
OEO Elkayam
O Elkayam
Objective: To assess the effect of rituximab on the efficacy and safety of influenza virus vaccine in patients with rheumatoid arthritis (RA). Methods: The study group comprised patients with RA treated with conventional disease-modifying drugs with or without rituximab. Split-virion inactivated vaccine containing 15 μg haemagglutinin/dose of B/Shanghai/361/02 (SHAN), A/New Caledonian/20/99 (NC) (H1N1) and A/California/7/04 (CAL) (H3N2) was used. Disease activity was assessed by the number of tender and swollen joints, duration of morning stiffness and evaluation of pain on the day of vaccination and 4 weeks later. CD19-positive cell levels were assessed in rituximab-treated patients. Haemagglutination inhibition (HI) antibodies were tested and response was defined as a greater than fourfold rise 4 weeks after vaccination or seroconversion in patients with a non-protective baseline level of antibodies (<1/40). Geometric mean titres (GMT) were calculated in all subjects. Results: The participants were divided into three groups: RA (n = 29, aged 64 (12) years), rituximab-treated RA (n = 14, aged 53 (15) years) and healthy controls (n = 21, aged 58 (15) years). All baseline protective levels of HI antibodies and GMT were similar. Four weeks after vaccination, there was a significant increase in GMT for NC and CAL antigens in all subjects, but not for the SHAN antigen in the rituximab group. In rituximab-treated patients, the percentage of responders was low for all three antigens tested, achieving statistical significance for the CAL antigen. Measures of disease activity remained unchanged. Conclusion: Influenza virus vaccine generated a humoral response in all study patients with RA and controls. Although the response was significantly lower among rituximab-treated patients, treatment with rituximab does not preclude administration of vaccination against influenza.

14 January 2016 in Der Schmerz
Verified
Journal Article
Closed access
PDF file
MFM.-A. Fitzcharles
M.-A. Fitzcharles
CBC. Baerwald
C. Baerwald
Jacob AblinJacob Ablin
Jacob Ablin
WHWinfried Häuser
Winfried Häuser

21 November 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
Jacob AblinJacob Ablin
Jacob Ablin
MFMary-Ann Fitzcharles
Mary-Ann Fitzcharles
DBDan Buskila
Dan Buskila
YSYoram Shir
Yoram Shir
CSClaudia Sommer
Claudia Sommer
WHWinfried Häuser
Winfried Häuser
Objective.Current evidence indicates that there is no single ideal treatment for fibromyalgia syndrome (FMS). First choice treatment options remain debatable, especially concerning the importance of complementary and alternative medicine (CAM) treatments.Methods.Three evidence-based interdisciplinary guidelines on FMS in Canada, Germany, and Israel were compared for their first choice and CAM-recommendations.Results.All three guidelines emphasized a patient-tailored approach according to the key symptoms. Aerobic exercise, cognitive behavioral therapy, and multicomponent therapy were first choice treatments. The guidelines differed in the grade of recommendation for drug treatment. Anticonvulsants (gabapentin, pregabalin) and serotonin noradrenaline reuptake inhibitors (duloxetine, milnacipran) were strongly recommended by the Canadian and the Israeli guidelines. These drugs received only a weak recommendation by the German guideline. In consideration of CAM-treatments, acupuncture, hypnosis/guided imagery, and Tai Chi were recommended by the German and Israeli guidelines. The Canadian guidelines did not recommend any CAM therapy.Discussion.Recent evidence-based interdisciplinary guidelines concur on the importance of treatment tailored to the individual patient and further emphasize the need of self-management strategies (exercise, and psychological techniques).

1 May 2008 in Joint Bone Spine
Verified
Journal Article
Closed access
Jacob AblinJacob Ablin
Jacob Ablin
LNLily Neumann
Lily Neumann
DBDan Buskila
Dan Buskila

22 December 2006 in Pharmacogenomics
Verified
Journal Article
Closed access
DBDan Buskila
Dan Buskila
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini
Jacob AblinJacob Ablin
Jacob Ablin
Fibromyalgia syndrome (FMS) is a common chronic widespread pain syndrome mainly affecting women. Although the etiology of FMS is not completely understood, varieties of neuroendocrine disturbances, as well as abnormalities of autonomic function, have been implicated in its pathogenesis. The exposure of a genetically predisposed individual to a host of environmental stressors is presumed to lead to the development of FMS. Fibromyalgia overlaps with several related syndromes, collectively compromising the spectrum of the functional somatic disorder. FMS is characterized by a strong familial aggregation. Recent evidence suggests a role for polymorphisms of genes in the serotoninergic, dopaminergic and catecholaminergic systems in the etiopathogenesis of FMS. These polymorphisms are not specific for FMS and are similarly associated with additional comorbid conditions. The mode of inheritance in FMS is unknown, but it is most probably polygenic. Recognition of these gene polymorphisms may help to better subgroup FMS patients and to guide a more rational pharmacological approach. Future genetic studies conducted in larger cohorts of FMS patients and matched control groups may further illuminate the role of genetics in FMS.